Is Thymosin Alpha-1 Legal in Oregon? How to Access It Legally

Print or save as PDF

Key numbers

  • 4 yes and 17 noFDA advisory committee vote on thymosin alpha-1 compounding, December 2024Source: fda.gov, as cited Nov 7, 2026
  • 1.6 mgZadaxin strength per vial, a finished injection sold outside the USSource: fda.gov, as cited Nov 7, 2026
  • 28-amino-acidLength of the thymosin alpha-1 peptide chain, the substance FDA's records coverSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / Not approved; no US application found [1]
  • Orphan designations / Four US designations, not approvals [1]
  • State-licensed pharmacy list / In none of the three categories [2]
  • Outsourcing-facility list / Category 3, nominated without adequate support [3]
  • FDA advisory vote / 4 yes and 17 no, December 4, 2024 [4]
  • HHS peptide policy / Not among the six peptides in the October 2026 draft [5]
  • Approved outside the US / Zadaxin, in Italy, India and Hong Kong [1]
  • US-approved dose / None exists [1]

What is thymosin alpha-1?

Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5 [1]. Thymalfasin is the synthetic version with the same sequence. Zadaxin is the brand of the finished injection sold outside the US, 1.6 mg per vial; it is not interchangeable with bulk thymosin alpha-1 powder [1].

Is it FDA-approved?

No. A Drugs@FDA search found no US application for thymosin alpha-1 [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1].

FDA lists national approvals in Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1]. A SciClone 2014 annual report claims approval in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, but FDA could not independently verify those broader claims [1]. Two older reviews by authors tied to the Zadaxin developer say it is approved in over 35 countries (2009) or more than 30 countries (2007) [6][7].

What is the federal compounding status?

FDA's page on bulk substances that may raise significant safety risks lists thymosin alpha-1 in the nominated but withdrawn table. It had been in category 2 for significant safety risks and came off that list when the nominators withdrew [8]. FDA's stated concerns remain on the page: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to sufficiently understand the extent of any safety issues [8].

What do FDA's compounding lists say about access?

There is no FDA-approved thymosin alpha-1 product and no US-approved dose [1]. On FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, it appears in none of the three categories [2]. On the outsourcing-facility list, updated March 21, 2025, it is category 3, nominated without adequate support [3]. Category 1, FDA's policy of generally taking no action against compounders that meet the conditions, does not apply to it [2][3].

In December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both thymosin alpha-1 free base and thymosin alpha-1 acetate [4]. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access [4]. Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].

Questions worth asking

Choose the questions you want to keep

Is it on WADA's Prohibited List?

Thymosin alpha-1 is not named on WADA's 2026 Prohibited List and is not named in the 2027 List [9]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 in S2.3, which is a different peptide [9]. WADA's S0 category covers substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [1][9].

Is thymosin alpha-1 legal in Oregon?
Federal records do not settle Oregon's position. Federally, it is not FDA-approved [1], it is in none of the three categories on FDA's list for state-licensed pharmacies [2], and it is category 3 for outsourcing facilities [3].
Can an Oregon pharmacy compound thymosin alpha-1?
FDA's category 1 policy does not apply to it, and it appears in none of the three categories on the state-licensed pharmacy list [2][3]. FDA's advisory committee voted 4 yes and 17 no in December 2024 on adding it to the pharmacy bulks list, and it is not in HHS's October 2026 draft peptide policy [4][5].
Is Zadaxin approved in the US?
No. Zadaxin is a finished 1.6 mg injection approved in some other countries, not the US, and it is not interchangeable with bulk thymosin alpha-1 powder [1].
Show all 9 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Oregon? How to Access It Legally